March 2017. Reviews health plan nominations of overall specialty manufacturer "Partner of Choice" and ratings of 30+ manufacturers in account support and willingness to contract for their specialty portfolios. Examines the evolving contracting environment across twelve specialty therapeutic classes and reveals opportunities for partnership.
November 2016. Examines managed care customer evaluations of manufacturer-sponsored specialty care management progams and resources and identifies unmet customer needs.
October 2016. Examines SPPs' manufacturer "Partner of Choice," manufacturer collaboration initiatives with SPPs, and and benchmark ratings of manufacturers in account support and willingness to contract. Examines the contracting environment across ten therapeutic classes and reviews best practices in engaging SPPs to better address issues in patient adherence and access.
October 2016. Provides an overview of specialty pharmaceutical spending over time by therapeutic class and distribution channel. Examines recent notable SPP market activity and trends, and SPPs' most pressing strategic imperatives. Examines SPP service offerings for health plans and manufacturers. Provides profiles for the top industry-leading specialty pharmacy providers.
August 2016. Examines current and future ACO initiatives in specialty and oncology management. Reviews specialist participation and compensation, specialty medication management tactics, and the status of quality metrics and clinical pathways adoption. Identifies opportunities for partnership.
June 2016. Reviews the market trends that may drive IDNs toward tighter management of specialty medications, IDNs' quality improvement priorities by specialty disease state, specialty medication management activity, and opportunities for partnership.
June 2016. Reviews recent biosimilar and specialty generic market entries, examines payer responses to the availability of these alternatives, and discusses implications going forward.
Commercial Health Plans: Manufacturer Account Engagement and Contracting for Specialty PharmaceuticalsThe competitive landscape is heightening across many specialty therapeutic classes as the pipeline delivers new product entries, from new molecular entities with novel mechanisms of action to...
Care management programs addressing specialty therapeutic areas are of critical importance to managed care customers; however, many experience notable gaps in the resources required to effectively...
Specialty medication manufacturers engage specialty pharmacy providers (SPPs) in a variety of ways, leveraging their ability to shape the brand experience and enhance access. HIRC’s report,...
The specialty drug spend is increasingly flowing through specialty pharmacy provider (SPP) and retail channels, yet the market remains highly concentrated and competitive. HIRC’s report, Specialty...
As ACOs plan for additional risk responsibility in the coming years, strategies for managing the cost and quality of care associated with oncology and specialty conditions are emerging. HIRC’s report...
The shift towards value-based care is likely to impact how providers think about and evaluate medications. HIRC’s report, Integrated Delivery Networks: Specialty Medication Management Initiatives and...
While the adoption and impact of biosimilars remains uncertain, commercial payers are optimistic that the resulting competitive environment will lead to specialty drug cost savings. HIRC’s report,...
As the specialty drug spend rises, payers are actively implementing new approaches and adjusting current strategies to moderate costs. HIRC’s report, Commercial Health Plans: Specialty Medication...
Payers remain focused on developing optimal cost and utilization strategies as the specialty drug spend continues to rise. HIRC's Specialty Pharmaceuticals Service assists pharmaceutical manufacturers in developing and maintaining successful market access strategies by monitoring trends in specialty medication management, as well as issues in distribution and specialty pharmacy provider engagement.
HIRC utilizes a triangulated research design, combining primary survey data, interview insights, and in-depth secondary research, resulting in a deep understanding of issues related to specialty pharmaceutical market access.
Therapeutic categories include:
- Cystic Fibrosis
- Crohn's Disease
- Hepatitis C
- Multiple Sclerosis
- PCSK9 Inhibitors
- Rheumatoid Arthritis
- White Blood Cell Stimulants
For more information or to subscribe, contact Danielle Snook via email or at (408) 884-8560
Covering the Specialty Market Ecosystem
The service monitors commercial health plan activities to manage the cost and utilization of specialty pharmaceuticals and tracks trends in contracting. Manufacturers' account support engagement, programs, and willingness to contract are assessed from the perspective of the customer. Trends in specialty drug distribution and manufacturer engagement in the specialty pharmacy provider (SPP) channel are also examined and monitored.
- Commercial Health Plans: Management Trends
- Commercial Health Plans: Manufacturer Engagement
- Specialty Pharmacy Providers: Channel Distribution Trends
- Specialty Pharmacy Providers: Manufacturer Engagement
Bringing Value to Subscribers
HIRC's data and insights enable subscribers to understand and track market dynamics and trends critical to optimal product and value-added program positioning as the specialty market evolves.
Through detailed analyses, key implications, and strategic recommendations from experienced HIRC researchers, subscribers to the Specialty Pharmaceuticals Service are able to understand the specialty pharmaceuticals market landscape, evaluate account support, identify specialty-specific managed care needs, and act upon partnership opportunities.